SCHEMBL5423232

SCHEMBL5423232

CCCC(NC(=O)C(CC(=O)N1CCOCC1)CC1CCCCC1)C(=O)c1nnc(CC)o1

nearest known ligand 0.50

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CTSS P25774 20/20 0.50
CTSK P43235 10/20 0.50
CTSL P07711 9/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14562908 1.00 CTSS (0.50) CTSSCTSKCTSL
SCHEMBL5428511 0.83 CTSS (0.49) CTSSCTSKCTSL
SCHEMBL14562966 0.78 CTSS (0.39) CTSSCTSKCTSL
SCHEMBL5424808 0.78 CTSS (0.39) CTSSCTSKCTSL
SCHEMBL5954924 0.77 CTSS (0.49) CTSSCTSKCTSL
SCHEMBL5954981 0.77 CTSS (0.49) CTSSCTSKCTSL
SCHEMBL5955892 0.77 CTSS (0.49) CTSSCTSKCTSL
SCHEMBL5954918 0.77 CTSS (0.49) CTSSCTSKCTSL
SCHEMBL5955883 0.77 CTSS (0.49) CTSSCTSKCTSL
SCHEMBL14562906 0.75 CTSS (0.56) CTSSCTSKCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-03-01 US claimed
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors AVENTIS PHARMACEUTICALS INC. (US) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049594-A1 Novel compounds and compositions as cathepsin inhibitors CTSS, CTSB, CTSE CTSS 1/4885CTSK 8/4885CTSL 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.